Orthopedics

Your Article Summary

See Latest Articles

Age as a prognostic factor for patients with osteosarcoma: an analysis of 438 patients
Journal of Cancer Research & Clinical Oncology, 10/01/09

Harting MT et al. – Age at diagnosis does not appear to be a significant independent prognostic variable for overall survival or disease-free survival in patients with osteosarcoma. Although our data indicate that patients in the fifth decade and older fare worse than younger patients, other variables such as tumor necrosis, tumor extension, and tumor location are likely responsible for the observed decline in overall survival and disease-free survival

• 438 patients
• All ages
• Diagnosed with osteosarcoma between 1 January 1980 and 31 December 2000
• Underwent the majority of their treatment at M.D. Anderson Cancer Center (MDACC)
• Patient and tumor specific variables collected including patient demographics, patient history, primary tumor information, treatment strategy , metastatic disease information, long-term follow-up, and eventual outcome
• Statistical analyses, including univariate and multivariate analyses performed, with overall survival and disease-free survival as primary outcome measures

• Median age at diagnosis was 18.1 years (range 2 months to 78.8 years)
• Median follow-up 4.2 years (range 5 days to 22.8 years) for all patients and 12.3 years (range 1 month to 22.8 years) for 209 surviving patients
• Survival rates at 5, 10, and 15 years were 54.1, 47.2, and 45.2%, respectively
• On univariate analyses, age ≥ 40 was found to be a poor prognostic factor
• Other prognostic factors included tumor size, metastasis at diagnosis, soft-tissue tumor extension, surgery type, chemotherapy group, and tumor necrosis
• Age not identified a statistically significant prognostic variable on multivariate analysis




<< Previous Biological reconstruction after resection of bone tumours around...

Next >> Total hip replacement in patients with neurological conditions

Today in Oncology...keeping you current

Receive free subspecialty "5-minute updates" via email

A phase 2 trial exploring the effects of high-dose (10,000 IU/day) Vitamin D3 in breast cancer patients with bone metastases
Cancer, 11/25/09

Endoprosthetic proximal femur replacement: Metastatic versus primary tumors
Surgical Oncology, 11/05/09

Pediatric osteogenic sarcoma
Current Opinion in Pediatrics, 11/17/09

See All of Oncology